January 2004
European Chemical News;1/26/2004, Vol. 80 Issue 2084, p25
Trade Publication
Presents an update on technology used in the European chemical industry as of January 2004. Launch of the European hydrogen and fuel cell technology platform; Establishment of a subsidiary by bioinformatics specialist Matrix Science of London in Tokyo, Japan; Decision of Biotie Therapies to focus its operation in Turku, Finland.


Related Articles

  • NEWS IN BRIEF. Tyler, Alan // European Chemical News;11/29/2004, Vol. 81 Issue 2126, p24 

    Presents news briefs on the fine chemicals industry as of November 29, 2004. Acquisition of Avecia's Special Drug Mixtures business by Copperhead Chemical; Amount of funding granted by Finland's national technology agency Tekes to Biotie Therapies for its small molecule inhibitor program;...

  • First Finnish biotech IPO. Lahteenmaki, Riku // Nature Biotechnology;Jul2000, Vol. 18 Issue 7, p699 

    Reports on plans of Turku, Finland-based developers of drug, BioTie Therapies to raise funds on the Helsinki Stock Exchange for development-stage biotechnology companies. Amount to be raised by BioTie; Purpose of providing financial support to biotechnology companies.

  • Financings Roundup.  // BioWorld Today;3/15/2011, Vol. 22 Issue 50, p4 

    The article reports on the completion of a private placement of nearly 50 million shares by Biotie Therapies Corp. of Turku, Finland.

  • Other News To Note.  // BioWorld Today;12/14/2011, Vol. 22 Issue 240, p2 

    This section offers news briefs concerning the biopharmaceutical industry. BioLineRx Ltd. of Jerusalem and Compugen Ltd. of Israel collaborated to develop new drugs. Biotie Therapies Corp. signed a collaborative research and development agreement with the National Institute on Drug Abuse for a...

  • Biotie, Lundbeck See Success in Alcohol Dependence Trial.  // Bioworld Week;1/10/2011, Vol. 19 Issue 2, p3 

    The article reports on the success of two Phase III studies of nalmefene for alcohol dependence developed by Biotie Therapies Corp. and licensed to H. Lundbeck A/S for nalmefene, a therapy that does not need abstention from alcohol.

  • Biotie Beefs up CNS Pipe with $120M Synosia Buy.  // Bioworld Week;1/17/2011, Vol. 19 Issue 3, p3 

    The article reports on the move of Biotie Therapies Corp. to acquire Synosia Therapeutics Holding AG for about 120.95 million dollars for bringing in six clinical stage central nervous system (CNS) products including treatments for Parkinson's and Alzheimer's diseases and for bipolar disorder.

  • Acorda offers $363M to acquire Finnish biotech company. GOLDEN, JOHN // Westchester County Business Journal;1/25/2016, Vol. 52 Issue 4, p9 

    The article reports on the decision of Acorda Therapeutics Inc., Westchester County, N.Y.'s biotechnology company, to pay 363 million U.S. dollars to acquire Finnish biotech company Biotie Therapies Corp. and mentions views of Ron Cohen, Acorda's founding president, on the deal.

  • SOMAXON EXERCISES OPTION TO LICENSE NALMEFENE.  // Worldwide Biotech;Jan2005, Vol. 17 Issue 1, p1 

    Reports on the cooperation and option agreement signed by Biotie Therapies Corp. and Somaxon Pharmaceuticals Inc. on nalmefene in July 2004. Terms of the agreement; Amount of license fee to be paid by Somaxon to Biotie; Information on nalmefene.

  • Biotie, Elbion Combining Pipelines in Stock Deal.  // Bioworld Week;11/3/2008, Vol. 16 Issue 44, p2 

    The article reports on the decision of biotechnology companies Biotie Therapies Corp. and Elbion AG to combine their pipelines and resources in an all-stock transaction in Europe. Under the deal, Biotie will issue 46.8 million new shares to Elbion and would own about two-thirds of the company....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics